Adilia Hormigo, MD, PhD, director of the Neuro-Oncology Program, professor of neurology, neurosurgery, and medicine, Tisch Cancer Institute, Mount Sinai Hospital, discusses the current treatment landscape of glioblastoma.

Glioblastoma is a grade 4 astrocytoma and is the most malignant and frequent form of glioma observed in patients, explains Hormigo.

Upon diagnosis, the standard of care treatment is chemoradiation, Hormigo says. However, survival rates remain poor.

Moreover, there is no established standard of care regimen for patients with recurrent glioblastoma as no therapies have demonstrated a prolonged survival benefit, continues Hormigo.

While bevacizumab (Avastin) is approved in patients with glioblastoma who have progressed following prior therapy, research efforts should be aimed at developing additional therapies and determining which subsets of patients are likely to respond to the available options, concludes Hormigo. 

Videos

Adilia Hormigo, MD, PhD, discusses the current treatment landscape of glioblastoma.  



Dr. Hormigo on the Current Treatment Landscape of Glioblastoma 

Adilia Hormigo, MD, PhD, director of the neuro-oncology program, professor of neurology, neurosurgery, and medicine, Tisch Cancer Institute, Mount Sinai Hospital, discusses the impact of the coronavirus disease 2019 (COVID-19) on high density areas.

There have been less admissions to the intensive care unit at Mount Sinai and other metropolitan hospitals, suggesting that New York City may be past the peak of COVID-19, says Hormigo.

However, it is hard to determine when the city can safely begin to open. When the city does reopen, it is unlikely to operate as it did prior to the pandemic, says Hormigo. For such dense areas such as New York City, it will be difficult to enforce social distancing.

Adilia Hormigo, MD, PhD, discusses the impact of the coronavirus disease 2019 (COVID-19) on high density areas.

Adilia Hormigo, MD, PhD

Articles

Dr. Hormigo on the Current Treatment Landscape of Glioblastoma

Dr. Hormigo on the Impact of COVID-19 on High Density Areas